All Updates

All Updates

icon
Filter
Partnerships
RevolKa partners with Daiichi Sankyo for AI engineered protein development
AI Drug Discovery
May 27, 2024
This week:
Funding
Lhyfe receives EUR 11 million grant from Klimatklivet for green hydrogen project in Sweden
Hydrogen Economy
Yesterday
Product updates
XRAI Glass launches AR One glasses at USD 1449 for hearing-impaired individuals
Extended Reality
Yesterday
Funding
VR therapy platform CUREosity raises EUR 3.8 million in funding to expand market presence
Extended Reality
Yesterday
Last week:
Product updates
Coinbase updates mobile wallet to add decentralized app browser
Decentralized Finance (DeFi)
Jun 22, 2024
Product updates
Coinbase updates mobile wallet to add decentralized app browser
Web3 Ecosystem
Jun 22, 2024
M&A
OpenAI acquires Rockset to power retrieval infrastructure
Data Infrastructure & Analytics
Jun 21, 2024
M&A
OpenAI acquires Rockset to power retrieval infrastructure
Foundation Models
Jun 21, 2024
Partnerships
Product updates
Anthropic releases Claude 3.5 Sonnet, the first model in the 3.5 series
Foundation Models
Jun 21, 2024
Funding
Paramount Planet Product raises USD 1 million in federal grant funding to support commercialization
Bio-based Materials
Jun 21, 2024
Regulation/policy
Apple delays launch of Apple Intelligence features in EU citing regulatory concerns
Generative AI Applications
Jun 21, 2024
AI Drug Discovery

AI Drug Discovery

May 27, 2024

RevolKa partners with Daiichi Sankyo for AI engineered protein development

Partnerships

  • AI-based Biotechnology company RevolKa and pharmaceutical company Daiichi Sankyo and have entered a drug development partnership. Details of this agreement and financial terms were undisclosed.

  • According to the partnership, RevolKa will be committed to creating and delivering highly functional proteins, leveraging Daiichi Sankyo’s proprietary protein engineering platform technology, called "aiProtein," an AI-integrated protein engineering technology. 

  • Tokyo-based RevolKa is a biotechnology company specializing in the development of highly functional proteins using AI. The company leverages its proprietary aiProtein technology to accelerate the creation of engineered proteins. RevolKa’s pipeline includes several programs spanning therapeutic areas of immuno-oncotherapy, rare diseases, oncology, and infectious diseases.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.